MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
Go back to MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity| (NASDAQ: MTVA) | Delayed: 1.74 -0.27 (13.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.01 | 52 Week High | $ | |||
| Open | $1.88 | 52 Week Low | $ | |||
| Day High | $2.17 | P/E | N/A | |||
| Day Low | $1.72 | EPS | $ | |||
| Volume | 592,813 | |||||
